Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR...
April 27, 2023 10:14 ET | Source: Nuvectis Pharma, Inc.

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is...
April 27, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
April 18, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinomaResearch conducted by investigators from the Mayo Clinic in Rochester, MN Fort...
April 10, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Fort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
March 17, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
March 10, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
March 07, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian CarcinomaENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer...
February 23, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

Fort Lee, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of...
February 09, 2023 08:00 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

FORT LEE, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of...